Dec. 2,
2005 |
|
6:30-8:30
pm |
Register
and collect the foreign guest materials and join in an informal
reception (Leader Hotel & Resort) |
|
Dec. 3,
2005 |
|
8:00
am |
Registration
(Taipei Youth Activity Center 6F) |
Session 1: Drug
Discovery and Development |
|
8:30¡V9:00
am |
Opening
remark |
|
9:00¡V9:10
am |
Introduction
Dr. Yu-Sheng Chao,
Director,
Division of Biotechnology & Pharmaceutical Research,
National Health
Research Institute |
|
9:10¡V10:00
am |
Keynote
speaker
Dr. Yale
Mitchel,
Executive
Director, Clinical Research Merck & Co.,
Inc., USA |
|
10:00-10:15
am |
Morning
break |
|
10:15-10:20
am |
Introduction
Dr. Jen Chen,
President, Genovate
Biotechnology Co., Taiwan |
|
10:20-11:00
am |
Dr. Frank
Martin,
Chief
Scientific Officer, iMEDD, Inc, USA |
|
11:00-11:05
am |
Introduction
Prof. Song-Nan Chow,
President of Taiwan
Foundation for the Development of Biomedical
Technology |
|
11:05-11:45
am |
¡§GSK HPV
Vaccine Development : Status and Future perspective¡¨
Dr.
Marie-Therese Martin,
Associate
Director, Late Development HPV Vaccine,
Belgium |
|
11:45
am-12:15 pm |
Prof.
Ann-Lii Cheng,
College of
Medicine, National Taiwan University, Taipei,
Taiwan |
|
12:15
pm-1:25 pm |
Mid-day
break |
|
Session 2
: Novel Anticancer Therapeutics (I) |
|
1:25-1:30
pm |
Introduction
Prof. Ji-Wang Chern,
School of
Pharmacy, National Taiwan University |
|
1:30-2:10
pm |
¡§Development
of Factor VIIa Inhibitors for the Treatment of Cardiovascular
Disease¡¨
Dr. Wendy
B. Young,
Senior
Director, Medicinal Chemistry, Celera Genomics, California,
USA |
|
2:10-2:15
pm |
Introduction
Prof. Cherng-Chyi
Tzeng,
Kaohsiung Medical
University |
|
2:15-2:45
pm |
¡§Targeting
Akt Signaling in Cancer Therapy. Opportunities and
Challenges¡¨
Prof. C.
S. Chen, PhD,
College
of Pharmacy, Ohio State University, Ohio, USA |
|
2:45-3:15
pm |
¡§Immunomodulators
as potential liver protectants for treating of hepatitis¡¨
Dr. Edwin
Wu,
President
and CSO, Jenken Biosciences, Inc., USA |
|
3:15-3:30
pm |
Afternoon
Break |
|
Session
3: Novel Anticancer Therapeutics (II) |
|
3:30-3:35
pm |
Introduction
Prof. Jih-Hwa Guh,
School of
Pharmacy, National Taiwan University |
|
3:35-4:15
pm |
¡§The Development of Novel Aminopyrazoles with
Anti-angiogenesis and Tumor Cells Anti-proliferation Activities for
Cancer Therapy¡¨
Dr. Chih
Yung Ho,
R. W.
Johnson Pharmaceutical Research Institute, USA |
|
4:15-4:20
pm |
Introduction
Prof. Jih-Hwa Guh,
School of
Pharmacy, National Taiwan University |
|
4:20-5:00
pm |
"Development
of Recombinant Desirudin ¡V an Anticoagulant Found in Leech"
Dr. Cheng
Der Tony Yu,
President &
Chief Scientific Officer, Canyon Pharmaceuticals, Inc., Hunt Valley,
Maryland, USA |
|
5:00
pm |
Adjourn |
|
6:00-7:00
pm |
Round
Table Discussion: Cultivation of Drug Development in Taiwan
Chairman:
Prof. Song-Nan Chow, M.
D,
President of Taiwan
Foundation for the Development of Biomedical
Technology |
|
7:00¡V09:30
pm |
Welcome
Banquet
(Sheraton
Taipei Hotel 17F for invited speakers only) |
|
Dec. 4,
2005 |
|
8:00
am |
Registration
(Taipei Youth Activity Center 6F) |
|
Session
4: Novel Anticancer Therapeutics (III) |
|
8:30-8:35
am |
Introduction
Prof.
C.M. Tseng,
National Taiwan
University |
|
8:35-9:15
am |
"Targeted
anticancer therapy - the Glivec story"
Dr. Alex
Matter, M.D., Director,
Novartis Institute for Tropical Diseases |
|
9:15-9:20
am |
Introduction
Prof. Ding-Shinn Chen,
Dean,
College of Medicine, National Taiwan University |
|
9:20-10:00
am |
Dr. John
Kavanagh, MD,
Houston,
USA |
|
10:00-10:15
am |
Morning
Break |
|
Session
5: Novel Anticancer Therapeutics (IV) |
|
10:15-10:20
am |
Introduction
Prof. Ling-Wei Hsin,
School of
Pharmacy, National Taiwan University |
|
10:20-11:00
am |
¡§Farnesyltransferase
Inhibitors as Cytostatic Agents¡¨
Dr.
Laurence I. Wu,
Vice
President, Drug Discovery, PharmaEssentia Corp, Taipei,
Taiwan. |
|
11:00-11:05
am |
Introduction
Prof. An-Rong Lee,
National Defense
Medical Center |
|
11:05-11:45
am |
¡@
¡@
¡@ |
|
11:45
am-12:15 pm |
¡§Development
of Targeted Delivery¡¨
Dr.
Keelung Hong,
Chairman
& CEO, Taiwan Liposome Company, Taipei,
Taiwan |
|
12:15¡V1:15
pm |
Mid-day
break |
|
Session
6: Recent Development of Antiviral
agents: |
|
1:15¡V1:20
pm |
Introduction
Dr. Ko-Chung Lin,
Pharmaessentia Corp,
Taiwan |
|
1:20-2:00
pm |
Prof.
George K.K Lau, MD, PhD,
Assistant
Dean of Faculty of Medicine, The University of Hong Kong,
China |
|
2:00-2:05
pm |
Introduction
Dr. Ko-Chung Lin,
Pharmaessentia Corp,
Taiwan |
|
2:05-2:45
pm |
Dr. Yibin
Xiang,
Senior
Director, Medicinal Chemistry, Genzyme Corporation,
USA |
|
2:45-3:15
pm |
Dr.
Kuei-Ying Lin,
Group
Leader, Drug Discovery, Gilead Sciences, Inc., California,
USA |
|
3:15-3:30
pm |
Afternoon
Break |
Session 7:
Development of Antidepressant Therapeutics |
|
3:30-3:35
pm |
Introduction
Prof. Fan-Lu Kung,
School of
Pharmacy, National Taiwan University |
|
3:35-4:15
pm |
"Discovery
and Development of a Non-peptide Delta Receptor Agonist DPI-289: a
Potential Antidepressant of Fast Onset of Action"
Dr.
Kwen-Jen (Ken) Chang,
President-Asia
Pacific Operations & Chief Science Officer, Enhance Biotech
Inc., USA |
|
4:15-4:20
pm |
Introduction
Prof. C. S. Chen, PhD.,
College of Pharmacy,
Ohio State University, USA) |
|
4:20-5:00
pm |
Dr.
Tung-Ping Su
Yang Ming Medical
University, Taiwan
Dr.
Yao-Chang Xu,
Head,
Discovery Chemistry Research, Lilly Research Laboratories Lilly
Corporate Center, U.S.A |
|
5:00
pm |
Adjourn |
|
6:00
pm¡V9:30 pm |
Farewell
Banquet (Hai Pa Wang) |
|
Dec. 5~6,
2005 |
|
Symposium
excursion- two days tour to
Hualien |